Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)

Fig. 2

Pre-treatment features associated with DCB. a The top 20 genes detected by liquid biopsy pre- and early on-treatment were shown for the 83 patients. The prevalence of alterations in each gene is listed on the right. Mutation counts for each sample are shown at the top, followed by rows indicating the benefit of treatment and ctDNA molecular response. Patients who achieved DCB had lower ctDNA concentration (b) but higher bTMB level (c) than those who achieved NDB. d Patients who achieved DCB had higher normalized bTMB level compared to those achieved NDB. e Patients with high bTMB had longer PFS than those with low bTMB (median 11.5 months versus 6.3 months). f Patients with high normalized bTMB had longer PFS compared to patients with low normalized bTMB (median 11.7 months versus 8.8 months). PFS: progression-free survival; HR hazard ratios, CI confidence intervals, bTMB blood-based TMB, DCB durable clinical benefit, NDB no durable benefit. The red horizontal bar in the (b–d) represents the mean and error bar represent ± SD; P < 0.05 represents statistical significance

Back to article page